Proteon Therapeutics, Inc is a privately held biopharmaceutical company developing novel, first-in-class pharmaceuticals to address the medical needs of patients with renal and vascular diseases. Proteon Therapeutics’ first drug candidate, PRT-201, is a locally-acting recombinant human elastase that fragments elastin fibers in blood vessel walls. Proteon is investigating whether elastase could be used as a treatment to dilate arteries and veins and to reduce neointimal hyperplasia in settings where such effects would result in a medical benefit. The Company is initially evaluating whether PRT-201 can improve the outcomes associated with the surgical creation of vascular accesses in chronic kidney disease patients undergoing hemodialysis. PRT-201 has received FDA fast track and orphan drug designations for hemodialysis vascular access indications.